trending Market Intelligence /marketintelligence/en/news-insights/trending/gypqohf6k4wwvyv9rzlvta2 content esgSubNav
In This List

DanDrit Biotech applies to list on Nasdaq

Blog

Global M&A By the Numbers: Q3 2021

Blog

Post-webinar Q&A: Global Credit Risk Trends 2021 and Beyond

Blog

University Essentials: From Crisis to Resilience – Navigating Sustainable Recovery

Blog

EV impact; vaccines to boost job market; coal supply constraints


DanDrit Biotech applies to list on Nasdaq

DanDrit Biotech USA Inc. filed an application to list its common shares on the Nasdaq Capital Market following the acquisition of privately held Enochian Biopharma Inc.

The Danish biopharmaceutical company will change its name to Enochian BioSciences Inc. and relocate its headquarters to Los Angeles. It is currently listed on the OTC Pink market.

DanDrit specializes in developing immunotherapies for various types of cancer and is currently working on innovative treatments for HIV and colon cancer.